Organogenesis Holdings (ORGO) Net Income towards Common Stockholders (2016 - 2026)

Organogenesis Holdings' Net Income towards Common Stockholders history runs 11 years deep, the most recent figure standing at -$56.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 160.1% year-over-year to -$56.2 million; the TTM figure through Mar 2026 stood at -$13.1 million (up 36.0% YoY), while the FY2025 annual figure was $25.7 million, up 2838.74% from the prior year.
• Net Income towards Common Stockholders was -$56.2 million for Q1 2026 at Organogenesis Holdings, down from $40.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $40.8 million in Q4 2025 to a low of -$56.2 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$889647.1 across 5 years, with a median of $215000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders surged 1373.02% in 2023, then slumped 928.14% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $7.5 million in 2022, then tumbled by 107.59% to -$568000.0 in 2023, then surged by 1134.33% to $5.9 million in 2024, then surged by 593.82% to $40.8 million in 2025, then slumped by 237.77% to -$56.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$56.2 million (Q1 2026), $40.8 million (Q4 2025), and $14.5 million (Q3 2025), per Business Quant data.